Johnson & Johnson Innovation – JJDC

Founded 1973
Founders Bruce Rosengard Chris Picariello Paul Stoffels Scott Orchard Seema Kumar Sue Hohenleitner

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 48
Average round size
info
The average size of a deal this fund participated in
$45M
Portfolio companies 40
Rounds per year 1.00
Lead investments 8
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.19
Exits 5
Key employees Soon

Areas of investment

  • Health Care
  • Biotechnology
  • Medical
  • Medical Device
  • Pharmaceutical
Summary

The leading representative office of defined VC is situated in the Cambridge. The company was established in North America in United States. Johnson & Johnson Innovation u2013 JJDC appeared to be a CVC structure as part of the corporation.

The increased amount of exits for fund were in 2018. Speaking about the real fund results, this VC is 13 percentage points more often commits exit comparing to other organizations. This Johnson & Johnson Innovation u2013 JJDC works on 23 percentage points less the average amount of lead investments comparing to the other organizations. Deals in the range of 10 - 50 millions dollars are the general things for fund. The important activity for fund was in 2019. The fund is generally included in 2-6 deals every year.

The typical case for the fund is to invest in rounds with 5-6 participants. Despite the Johnson & Johnson Innovation u2013 JJDC, startups are often financed by Wildcat Capital Management, Johnson & Johnson Development Corporation, TPG Biotech. The meaningful sponsors for the fund in investment in the same round are Wildcat Capital Management, Whittier Ventures, VSP Global. In the next rounds fund is usually obtained by dRx Capital, Lux Capital, Lightstone Ventures.

For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Among the various public portfolio startups of the fund, we may underline Memebox, Fusion Pharmaceuticals, X-Vax Technology We can highlight the next thriving fund investment areas, such as Pharmaceutical, Therapeutics. Besides, a startup requires to be at the age of 4-5 years to receive the investment from the fund. The fund has no specific favorite in a number of founders of portfolio startups. In case when startup counts 5+ of the founder, the chance for it to get the investment is meager.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Johnson & Johnson Innovation – JJDC:
Typical Co-investors
Johnson & Johnson Innovation – JJDC is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Johnson & Johnson Innovation – JJDC:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Frog Capital United Kingdom, London
Upshift Partners United States, San Francisco
ICICI Prudential Mutual Fund India, Mumbai
Birk Venture Norway, Oslo
Equilibrium Capital United States, San Francisco
Peak Capital Partners United States, Provo
Ironside Ventures United States, West Newton
Bank One United States, Chicago
Harmony Medical -
Delta Dental United States, Oak Brook
Shenzhen Yizan Investment Management China, Shenzhen
TR Capital China, Hong Kong Island
McDonnell Ventures -
ULan Network -
Xinhu Holding -
Macquarie Infrastructure Partners Australia, Sydney
Inlign Wealth -
Yamanashi Chugin Management Consulting Japan, Kofu
VENTA GROUP -
Venture Center India, Pune

Notable deals

CompanyIndustryRoundRound SizeDateInvestorsLocation

Visus Therapeutics

Biotechnology
Therapeutics
n/a
$20M10 Aug 2021 United States, Seattle

Iterative Scopes

Computer Vision
Health Care
Health Diagnostics
Medical
1
$30M03 Aug 2021 United States, Cambridge

Point Biopharma

Biopharma
Biotechnology
Therapeutics
n/a
$165M01 Jul 2021 United States, Indianapolis

Thirty Madison

Health Care
Personal Health
Pharmaceutical
Wellness
1
$140M02 Jun 2021 United States, New York

Health Care
Health Diagnostics
Life Science
Medical
Medical Device
Wellness
1
$235M13 May 2021 United States, San Diego

Biotechnology
Health Diagnostics
Therapeutics
1
$11M20 Apr 2021 United Kingdom, Cambridge

Sunday2Sunday

Beauty
Consumer Goods
Cosmetics
1
$4M25 Mar 2021 United States, New York

Visus Therapeutics

Biotechnology
Therapeutics
1
$36M09 Mar 2021 United States, Seattle

TechsoMed

Biotechnology
Health Care
1
$7M03 Mar 2021 Israel, " Israel"}
News
Visus Therapeutics Raises $20M in Funding

– Visus Therapeutics from Seattle develops innovative ophthalmic therapies to improve vision for people around the world.
– The company raised $20m in funding.
– The round was led by LSP in Amsterdam with participation from Sage Partners of Hong Kong, Johnson & Johnson Innovation -JJDC, Inc. and other inside investors.
– The new investment will be used to advance its clinical and commercial efforts for lead asset BRIMOCHOL under investigation for presbyopia as well as new research and development activities in its drug development pipeline.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Johnson & Johnson Innovation – JJDC?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!
Crunchbase icon

Content report

The following text will be sent to our editors: